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Objeefives. Do the benefits of intensive lipid-lowering therapy
extend to patients with only borderline or moderately elevated
levels of low density lipoprotein (LDL) cholesterol?
Background. The merits of the present LDL cholesterol treat-
ment goal of 5100 mg/dI need to be clarified for patients without
high levels of LDL cholesterol, particularly for those patients
previously classified as having only borderline high (130 to 159
mg/dl)
or desirable (101 to 130 tang/dl) levels .
Methods. Disease change and clinical events were examined in
LDL cholesterol subgroups in the Familial Atherosclerosis Treat-
ment Study (FATS) trial, a randomized, blinded, quantitative
arteriogrophic comparison of one conventional and two intensive
lipid-lowering strategies in men with coronary artery disease, a
positivc family history and apolipoprotein B =I25 mg/d-1 . The
primary end point, disease change per patient, was measured as
the mean change in severity of stenosis (A%S n.0 among nine
standard proximal segments.
Results. Ofthe 120 patients completing the 30-month protocol,
60 had a baseline LDL cholesterol <901h percentile (mean LDL
cholesterol 152 mg/dl) and 60 >90th percentile (mean LDL
cholesterol 221 mg/dl). Thirty-one patients had levels < 160 mg/di
(mean LDL cholesterol 134 rang/dl) and 89 > 160 nag/dl (mean LDL
cholesterol 205 mg/dl) . Patients with LDL cholesterol <901h
The majority of patients with coronary heart disease do not
have high total serum or low density lipoprotein (LDL)
cholesterol, as defined by 90th or 95th percentile cut points.
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LIPIDS
percentile benefited angiographically from therapy (A%O., =
- 13% diameter MenuAs h9siml during intensive therapy vs .
+2,3% diameter stenosis [progression] during conventional ther-
apy, p < 0.01), as did patients with LDL cholesterol <160 nag/dl
(A%Sp,. % = -4.2% vs. +3,3% diameter stenosis, p = 0.0001) .
By
comparison,
angiographic benefit was less pronounced among
those entering with very high LDL cholesterol (A%Sp,.. =
-0.2% vs. +1.9% diameter stenosis, p = 0.07) or with LDL
cholesterol X160
mg/d1
(A%Sp,., = +0.2% vs. +1 .6% diameter
stenosis, p = 0.13). Intensive therapy resulted in a statistically
significant reduction in clinical events only in the subgroup with
baseline LDL cholesterol <90th percentile (2 of 42 vs. 8 of 29
patients initially enrolled, p = 0 .01) and a trend toward fewer
events in patients with LDL cholesterol <160 mg/dl (2 of 20 vs . 6
of 15 patients, p = 0.05). No such difference was seen in the higher
LDL cholesterol subgroups .
Conclusions . Treatment benefit in the FATS trial was not
confined to patients with very high levels of LDL cholesterol and
was in fact particularly evident in those patients with levels
<160 tug/dl . Such patients should be considered more likely, not
less, to benefit from intensive lipid-lowering therapy .
(J Ana Cob Cardiol 1994,23.899-906)
899
In patients screened for the Multiple Risk Factor Interven-
tion Trial (MRFIT) (1), with no previous hospital stay for
myocardial infarction, nearly two-thirds of the coronary
heart disease mortality occurred in men with a total serum
cholesterol <245 mg/dl, which represents approximately the
80th percentile cut point for the MRFIT population (1) .
Genest et al . (2) studied 102 patients with premature coro-
nary heart disease (<60 years old) and found LDL choles-
terol >90th percentile in only 11% (2) .
In the setting of established cardiovascular disease, a
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mild elevation in total cholesterol or LDL cholesterol is a
clear risk factor for future coronary events . In
the placebo
group of the Coronary Drug Project (3), the 5-year rate of
coronary death and definite nonfatal myocardial infarction
was 24% greater in men in the second quintile of total
cholesterol (215 to 238 mg/dl) compared with men in the
lowest quintile (<215 mgldl) . In the Lipid Research Clinics
follow-up study, the age-adjusted rate of death from coro-
nary heart disease was significantly higher (h ratios
>3.0) in male patients with mildly elevated total cholesterol
(200 to 239
mg/dl) or LDL cholesterol (130 to 159 mg/dl)
coo with patients with lower levels
(4) . This increased
relative risk attributable to even mild elevations in total or
L cholesterol is superimposed on the much higher abso-
lute risk for coronary events associated with established
disease, and thus the potential clinical benefit of lipid-
lowering therapy in such patients would appear to be sub-
s
	
tial (5) .
Such data have prompted the National Cholesterol Edu-
cation Program (NCEP) Expert Panel (6) to recommend an
"optimal" LDL cholesterol level :5100 mg/dl for patients
with established coronary heart disease. However, data
confirming angiographic or clinical benefit with intensive
lipid-lowering therapy in patients with coronary artery dis-
ease and only mild or even moderate elevations in total or
LDL cholesterol are limited . A subgroup of 78 patients with
baseline total cholesterol X240 mg/dl (mean total cholesterol
216 mg/dl) in the Cholesterol Lowering Atherosclerosis
Study (CLAS) had significantly less disease progression with
niacin and colestipol therapy than with placebo (global
change score 0 .3 vs 0 .7, p = 0 .03) (7). The benefit with drug
therapy in CLAS patients with baseline total cholesterol
>240 mg/dl kmean total cholesterol 270 mg/dl) was compa-
rable (global change score 0.3 vs . 0 .9, p = 0.001).
The Familial Atherosclerosis Treatment Study (FATS) (8) is
a randomized, blinded, quantitative io phic compari-
son of three lipid-altering strategies in men with established
coronary artery disease . There is a wide range of baseline
L cholesterol values in this population, selected because
of elevated total plasma apolipoprotein B . We examined the
FATS data to determine whether patients with only border-
line or moderate elevations in pretreatment LDL cholesterol
derived as much *ographic or clinical benefit, or both,
from intensive lipid-lowering therapy as patients with higher
levels of LDL cholesterol . In fact, they actually obtained
greater benefit than their more hyperlipidemic counterparts .
Methods
S y . The FATS trial enrolled men ed <63
years, with coronary heart disease, a family history of
premature cardiovascular events and pretreatment apoli-
poprotein B ' 125 mg/dl (mean level of two samples). The
design and execution of the trial have been described in
detail elsewhere (8). Briefly, 364 men, eligible in terms of
age, coronary disease, family history and apolipoprotein B
levels, were contacted about this trial between January 1984
and February 1987 . Of these, 132 were deemed ineligible
because of completed or scheduled revascularization (88
patients) or coexisting diabetes, severe hypertension, cancer
or liver, thyroid or kidney disease (44 patients) . Another 86
patients were eligible, but they or their physicians declined
participation . A total of 146 men were enrolled in the study .
At the initial visit, the patient read, discussed and signed a
consent form approved by the institutional review board
(approval date November 24, 1983) .
Subjects were randomly assigned to one of three treat-
ment groups: 1) niacin (4 glday) and colestipol (30 glday) ;
2) lovastatin (40 mgfday) and colestipol ; and 3) conventional
therapy with placebos for lovastatin and colestipol, unless
the LDL cholesterol level was >90th percentile for age, in
which case these patients (43% of the conventionally treated
group) received colestipol instead of placebo . All patients
received die counseling at each clinic visit. Bimonthly
visits spanned 2 .5 years between coronary arteriograms
(total radiation exposure -5 rem) . Quantitative coronary
angiography was performed as previously described for all
146 baseline films and for the film pairs of 120 patients
completing the protocol (9) . Briefly, cine films were viewed
at high (fivefold) magnification in a dual-overhead projection
system . An average of three frames per film in comparable
views and cycle points were selected as representative
images of each lesion. Borders of these selected images were
traced manually and measured digitally, and the three mea-
sures were averaged to provide a single estimate of stenosis
severity at each of the two time points . Lumen diameter was
measured at an
observer-specified
"normal" segment and at
the point of greatest narrowing, and percent diameter steno-
sis was calculated .
Plasma very low density lipoprotein (VLDL), LDL and
high density lipoprotein (HDL) cholesterol, triglycerides and
plasma apolipoprotein B were measured (10,11) at baseline
and quarterly at the Northwest Lipid Research Clinic labo-
ratory. A more detailed analysis, including apoli proteins
A-I and A-Il (12) and lipoprotein (a) (13), was performed at
baseline and at I and 2 years during therapy .
For the present analysis, patients were assigned to sub-
groups on the basis of their baseline LDL cholesterol level .
Subgroups analyzed included patients with baseline LDL
cholesterol below or above 1) the 90th percentile for age,
based on Lipid Research. Clinics Prevalence Study data (14)
(165, 186 and 191 mg/dl, respectively, for a 40-, 50- and
60-year old man), or 2) 160 mg/dl, specified by the NCEP
Expert Panel as the boundary between a borderline high risk
and high risk LDL cholesterol level for primary prevention
in adults (6). Hypertriglycerade is was defined as a plasma
level >200 mg/dl.
Statistical analysis, Within each LDL cholesterol sub-
group, differences between intensively treated (lovastatin
and colestipol or niacin and colestipol) and conventionally
treated patients were analyzed . The groups receiving lova-
statin and colestipol or niacin and colestipol were combined
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Figure L Location of nine standard proximal coronary artery seg-
ments (SEG) . The lesion causing the worst stenosis in each of these
segments was measured . The average (Ave) percent stenosis among
these segments was computed, and the mean change (A) in this value
between the two studies (time points A and B) was determined . This
estimate of the mean change in the severity of proximal stenosis
(here 4%) was determined for each patient . Reprinted, with permis-
sion, from Brown et al . (8) .
because their clinical and angiographic outcomes did not
differ in any significant respect .
Subgroup differences in baseline risk factors were com-
pared by one-way analysis of variance (ANOVA) for con-
tinuous variables and chi-square tests for categoric vari-
ables. The primary study end point was the average change,
during the 2 .5-year angiographic interval, in percent stenosis
for the worst lesion in each of nine proximal coronary artery
segment . A single estimate of the mean change in proximal
stenosis (A%Sp,,O.,) was made for each patient (as illustrated
in Fig. 1, A%Sp,( ,, = 4%). Differences between intensive and
conventional therapy for the mean value of this disease
change variable were compared by one-way ANOVA, and
treatment benefit relative to conventional therapy was com-
pared between LDL cholesterol subgroups by two-way
ANOVA.
A secondary end-point analysis compared the treatment
subgroups in terms of their frequency of "progression only"
(progression X109o' in at least one of the nine proximal
lesions without comparable regression) and "regression
only" (the converse) . A score was assigned to each patient
that classified them as having progression only, mixed or no
change or regression only, and subgroup differences were
compared by Kruskal-Wallis ANOVA (15) .
Subgroup differences in the proportion of patients who
had clinical events during the 2 .5 years of the study were
compared by the Fisher exact test. A difference was consid-
ered statistically significant if the two-sided probability of
the observed result under the null hypothesis was isO .05 .
Resubs
Baseline characteristics . As shown in Figure 2, a plot of
LDL cholesterol versus apolipoprotein B at the pretreatment
sample point, there is a wide range of baseline LDL choles-
terol values (80 to 323 mg/dl) in the 120 men selected for
apolipoprotein B at 125 mg/dl (mean level of two samples) .
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Figure 2 . Plot of low de,,sity lipoprotein cholesterol (LDLe) versus
apolipoprotein B (APO 13) for pretreatment baseline sample (n = 120
patients in the Familial Atherosclerosis Treatment Study) . Solid
lines = 90th percentile cut points for a 50-year old man ; dashed lines
= National Cholesterol Education Program guideline levels . In all
cases the screening and immediate pretreatment apolipoprotein B
levels averaged ? 125 mgldl .
Sixty patients had baseline LDL cholesterol <90th percen-
tile and 60 90th percentile for age (14) . In 31 patients it was
< 160 mg/dl, and in 89 patients it was > 160 mg/dl .
Patients with LDL cholesterol <90th percentile were
significantly older (50 vs . 45 years) and significantly more
likely to have a history of smoking (88% vs . 68%) or previous
myocardial infarction (50% vs . 30%) than patients with
higher LDL cholesterol (Table 1) . There were no significant
differe"ces in other nonlipid baseline risk factors between
the two subgroups . The randomization was well balanced for
risk, although in the subgroups with LDL cholesterol <90th
percentile, patients with intensive therapy were significantly
more likely than patients with conventional therapy to have
had a previous myocardial infarction (62% vs . 35%) (Table
1). In the subgroups defined by the 160-mg/dl cut point, and
by conventional and intensive treatment, there were no signif-
icant differences in nonlipid baseline risk factors (Table 2) .
Lipid, lipoprotein and apolipoprotein levels. As seen in
Table 1, patients with LDL cholesterol <90th percentile
had, at baseline, significantly lower mean total cholesterol
(241 vs . 298 mg/dl) ; LDL cholesterol (152 vs. 221 mg/dl),
HDL cholesterol (35 vs . 41 mg/dl), apolipoprotein B (140 vs .
168 mg/dl) and LDL/HDL cholesterol ratio (4.5 vs . 5 .5) than
their counterparts with higher LDL choiebterol and had
higher mean VLDL cholesterol (57 vs . 36 mg/dl) and total
triglycerides (261 vs . 159 mg/dl) . Mean baseline lipoprotein
(a) levels did not differ (32 vs . 40 Ing1di, p = 0 .24). A
significant difference, despite randomization, in baseline
lipids for conventional and intensive treatment subgroups
was limited to lipoprotein (a) in the LDL cholesterol 2t%th
percentile subgroup (Table 1) . Table I also shows mw?
., lipid
S32
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Baseline Characteristics and Lipid Responses in Subgroups With LDLc Above or Below the 90th Percentile
levels during treatment, and, as expected, both intensive
treatment subgroups had a much more striking change in
lipid levels than both conventional treatment subgroups. In
the intensive treatment subgroups, patients with LDL cho-
lesterol <90th percentile, compared with patients with LDL
cholesterol >90th percentile, had significantly lower in-
treatment total cholesterol (177 v, 212 mg/dl), LDL choles-
terol (98 vs . 135 mg/dl), apolipoprotein B (97 vs . 115 mg/dl)
and LDLIHDL cholesterol ratio (2.2 vs. 2.8) and signifi-
cantly higher total triglycerides (185 vs . 141 mg/dl) . How-
ever, the mean percent changes in lipid levels during treat-
ment in the two intensive treatment subgroups were very
similar (Table 1)
Similar determinations are shown in Table 2 for sub-
groups separated by the 160-mgldl cut point. As expected, all
patients in the lower LDL cholesterol subgroup, compared
with the higher LDL cholesterol subgroup, had significant
differences in other baseline lipids, including lower mean
total cholesterol (229 vs . 283 mgldl), apolipoprotein B (134 vs
161 mg/dl) and HDL cholesterol (33 vs 40 mg/dl) and higher
total triglycerides (302 vs . 178 mgldl). There were significant
differences, despite randomization, between conventional
and intensive treatment subgroups in some baseline lipids,
JACC Vol . 23, No . 4
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*p < 0.001 and tp < 0
.05, compared with all patients with low density lipoprotein cholesterol (LDLc) > 90th percentile by i t est . tp < 0.05 and §p < 0.001,
compared with conventional (CONY) therapy group patients by
t test
. (p < 0,001, ¶p <0 .05 and # p < 0
.01 . compared with intensive (tNT) therapy, LDLc 90th
percentile group patients by i test. CAD = coronary artery disease ; ElI = exercise treadmill test
; HDLc = high density lipoprotein cholesterol ; Htn
hypertension ; MI = myocardial infarction ; VLDLc = very low density lipoprotein cholesterol
; In - Rx = in-treatment levels
; %a = percent change .
particularly between the smaller treatment subgroups with
LDL cholesterol < 160 mg/dl . As in the 90th percentile LDL
cholesterol subgroups, the intensive treatment subgroups
had a far greater change in lipid levels than the conventional
treatment subgroups, and both intensive treatment subgroups
had similar mean percent changes in lipid levels (Table 2) .
Changes in mean severity of proximal stenosis . Results of
the primary study end point (AToSp,.j, defined in Figure 1,
are shown in Tables 3 and 4. Conventional therapy in all
subgroups resulted in disease progression (A%Sp,,, =
+1 .6% to +3 .3% diameter stenosis), and net disease regres-
sion was essentially limited to intensive therapy in the lower
LDL cholesterol subgroups . For patients with baseline LDL
cholesterol <90th percentile, intensive therapy resulted in
an average -1 .5% diameter stenosiss decrease in mean
severity of proximal skenosis (p = 0 .004 vs. conventional
therapy) . Striking disease regression occurred in the patients
with baseline LDL cholesterol < 160 mg/d1 (A-%Sp,.,
-4.2% diameter stenosis, p = 0 .0001 vs . conventional
therapy). These differences between intensive and conven-
tional therapy remained significant after elimination from the
analysis lesions that at baseline were totally occluded or had
>5VI9 diameter stenosis (Tables 3 and 4) .
LDLc <90th Percentile
LDLc a9Oth Perentile
All
(n = 60)
CONV
(n = 26) In - RX
INT
(n = 34) In - Rx (%a)
All
(n = 60)
CONV
(n = 20) In - Rx
INT
(n = 40) In - Rx (%A)
Conventional risk
Mean age (yr)
so*
49 50
45 45
45
History of Hin (%) 35
27
41 35 30 38
History of smoking (%)
81
94
68 60 73
Current smoking (%)
27 35
21
22 15 25
Body mass index (kg/m2)
27 27
27 27 25
27
CAD evidence
Previous MI (%) 50f
35 621;
30 25 33
Angina at entry (%)
73 77
71 62 55 65
Positive ETT (>2 mm) (%)
22 31
15 13
IS 13
Mean % proximal stenosis 34
31 36
33 V 35
Mean no . of proximal
1 .5 1 .3
1 .6 1 .3 Ll 1 .4
lesions >50%
Lipid risk
Cholesterol (mg/dl)
Total 241*
241 239 242 0711
N7) 298 292 273 300 212§ (-29)
LDLc
152* 145 143 157 98§11 (-37) 221
214 188 124 135§ (-40)
HDLc
35* 35 36 35 46§ (+30)
41 44 46 40 51 (+27)
VLDLc 57* 62 59
52 32§ (-22) 36 31 38 38 254 (-19)
Total triglycerides (mg/dl) 261*
294 287 236 185*T (-16) 159 145 165
166 141 (-10)
Apolipoproteins (mgldl)
B 140* 136 135
143 970 (-32) 168 166 152 169 115§ (-31)
191 129 130
124 129 140# (+10) 133 135 140 133 149 (+12)
oil
29 30 30 29 27 (-4) 30 31 30
29 29 (0)
Lipoprotein (a) (mg/dl) 32 29
28 34 28 (-12) 40 56 48 32t 27* (+10)
LDLc/HDLc ratio
4.5* 4.3 4 .1 4.7 2 .2§11 (-51) 5 .5 5
4
.2 5 .7 2.8§ (-52)
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Table 2 . Baseline Characteristics and Lipid Responses in Subgrou
*p < 0
.0005 and #p = 0 .05, compared with all patients with low density lipoprotein chokwaul >160 mg/dl by "at Q < 0 .0001, §p < 0 .05 and I < 0 .001,
compared with conventional therapy group patients by i test . Q < 0 .05 and Tp < 0 .0!, compared with intensive therapy group patients with low density
lipoprotein cholesterol >160 mg/dl by r test . Abbreviations as in Table 1 .
Patients with higher levels of baseline LDL cholesterol sis), and net dise-.se
regression was not substantially en-
did not achieve on average a similar degree of disease hanced in patients achieving low levels of in-treatment LDL
regression with intensive therapy (Li)L cholesterol >160 cholesterol or LDL/HDL cholesterol ratios (Tables 3 and 4) .
m/dl,
.A%SFr.,, = +0
.2% diameter stenosis ; LDL choles- In neither of the higher LDL cholesterol subgroups did the
terol ?90th percentile, A9o'Spo,, = -0.2% diameter steno-
	
difference in change of mean severity of proximal stenosis
Table 3. Mean per Patient Stenosis Change, Frequency of "Progression Only" and "Regression Only" and Clinical Events in Subgroups
by 90th Percentile Low Density Lipoprotein Cholesterol
STE, WART ET AL .
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With LDLc N60 or < NO tng/dl
<90th Percentile LDLc ?90th Percentile LDLc
*Patients received colestipol instead of its
placebo
. t
p
< 0AI, 0 = 0
.07 and §p < OIL compared with conventional therapy group patients by analysis of
variance . 11p < 0.025, compared with conventional therapy group patients by Kruskal-Wallis test . $146 patients, intention to treat
. op = 0 .01, compared with
convention! :arapy group patients by two-tailed Fisher exact test . Values presented are mean value ± SD or number (%)
. pis = patients ; other abbreviations
as in Table 1 .
LDLc < 50 mg/dl LDLc >TO QdI
All
(n = 31)
CONY
In = t5) hi - Rx
INT
(n = I
In - Rx
(z_el A,)
All
in = 89)
CONV
(n = 31) In - Rx
I N'T
(a = 58)
In - Rx
(%%A)
Conventional risk
Mean age (yr) 48 48 48 47 47 47
History of Htn (%) 32 40 25 36 23 43
History of smoking (%) 84 73 94 76 71 79
Current smoking (%) 32 33 31 21 23 21
Body mass idwc (kg!m') 28 29 27 27 25 27
CAD evidence
Previous MI (%) 48 33 63 37 29 41
Angina at entry (%) 74 73 75 65 65 66
Positive ETT (>2 mm) (%) 23 33 13 16 19 14
Mean % proximal stenosis 33 30 37 33 30 35
Mean no. of proximal 1 .3 1 .2 1 .4 ( .4 1 .3 1 .5
lesions >50%
Lipid risk
Cholesterol (mg/dl)
Total 229* 231 234 227 1721l (-25) 283 278 263 286 2021' (-29)
LDLc 134" 126 130 142§ 9511$ (-33) 205 199 178 208 1251 (-40)
HDLc 33* 30 32 35§ 4711 (+32) 40 43 44 38§ 49§ (+28)
VLDLc 64* 76 70 52 28I (-201 40 35 40 43 28§ (-20)
Total triglycerides (mgldl) 302* 366 346 242§ 172§ (-,2) 173 163 179 186 158 (-10)
Apolipoproteins (mg/dl)
B 134* 130 131 137 93t1 (-32) 161 159 148 163 1111 (-31)
A] 1270 126 122 128 145§ (+13) 133 135 136 132 145 (+11)
All 28 28 28 28 26 (-6) 30 31 31 29 29 (0)
Lipoprotein (a) (mg/dl) 27 19 19 34 28 (-23) 40 52 45 33§ 28§ (+6)
LDLc/HDLc ratio 4 .2* 4 .2 4 .1 4 .2 2.21 (-49)
i,3 4 .8 4 .1 5 .5§ 2 .61 (-52)
CONV
(n = 26)
INT
(n = 34)
CONV*
(n = 20)
INT
(n = 40)
Mean IMA proximal stenosis (±SD)
9 proximal lesions (n = 1,034) 2 .3 ± 3 .8
-1
.5 ± 5 .5t It 4.2
-0
.2 ± 3 .7t
In-treatment LDLc x100 mg/dl
-3
.0 ± 5 1 (n = 20) 0 .0 ± 1 .7 (n = 9)
In-treatment LDLc/HDLc ratio :52
-3
.2 ± 4 .8 (n = 14)
-0
.1 ± 3 .2 (n = 10)
Proximal lesiors with <100% stenosis (n = 997) 2 .4 ± 3 .9
-0
.7 ± 4 .4t 1 .9 ± 4 .2 0 .2 3
.7
Proximal lesions with <50% stenosis (n = 847) 2 .3 ± 3 .4 0.1
± 4 .3§ 2 .6 5 .1
0.4 3 .4
Progression Only 11(42%) 8(24%)
10(50,70) 9 (23%)
Regression Only 3 (12%) 15 (440/c)ll
2(10%) 11 (287011
Clinical events (total no . of pts at risk)q 8(29) 2 0&
2 (23) 3 (J2)
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TaW 4. Mean per Patient Stenosis Change, Frequency of "Progession Only"
and "Regression Only"' and Clinical Events in Subgroups
With Low Density Lipoprotein
Cholesterol >160 or <160 mg/dl
LDLc <160 mg/dl
between intensive and conventional therapy achieve statis-
tical significance, but there was a trend toward benefit in
both subgroups (LDL cholesterol 2:160 mg/dl, p = 0.13 ;
LDL cholesterol 2!90th percentile, p = 0 .07). Further sub-
division of the subgroup with LDL cholesterol a9Oth per-
centete into patients with and without hypertriglyceridemia
(co'nbined hyperlipidemia and type IIA hyperlipidemia, re-
opecdvely) did not reveal a group with a more striking
response to intensive therapy (OoSpro,, = -0.4% diameter
stenosis [n = 13] and -0.1% diameter stenosis [n = 27],
respectively).
The apparently greater benefit with intensive therapy in
the lower LDL cholesterol subgroups, relative to that in the
higher LDLc subgroups, reached statistical significance for
the 160- dl cut point only (p = 0 .0006 by two-way
ANOVA, p = 0.30 for treatment benefit comparison be-
tween 90th percentile subgroups) .
Intensive therapy in 18 FATS patients with lipid charac-
teristics of the subgroup most benefited by therapy in the
Helsinki Hkart Study (16) (non-HDL cholesterol a2OO mgtdl,
LDLAIDL cholesterol ratio >5 and triglycerides Qk mg,U)
resulted in an average +0.3% diameter stenosis increase in
mean severity of proximal stenosis (vs +2 .1% diameter steno-
sis in five such patients treated conventionally, p = 0.4) .
FIretIewyl; of ponlrawks amd zqpeaks. As seen in Ta-
bles 3 and 4, 44% of patients treated intensively in the
subgroup with LDL cholesterol <90th percentile had "re-
gression only" versus 12% of those treated conventionally
(p = 0.01). The corresponding frequencies of "regression
only" in the subgroup with LDL cholesterol <160 mg/dl
were 69% and 7% (p = 0.001) . In the higher LDL cholesterol
subgrotips, intensive therapy also significantly improved the
relative frequencies of "prijgression only" and "regression
only" (p < 0 .05), but only about one in four intensively
treated patients had regression only .
Frequency of clinical events . Clinical events are shown in
Tables 3 and 4 for the 146 enrolled patients in an intention-
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LDLc > 160
mg/d)
wenty patients received colestipol instead of its p lacebo. t p = 0,0001 and 1p < 0
.000i, compared with conventional therapy group patients by analysis of
vatiawc lp - 0 .001 and lip < 0,05, compared with conventional therapy group patients
. !146 patients, intention to treat
. *p = (1 .0i, compared with conventional
therapy group patients by two-tailed Fisher exact test .
Values presented are mean value ± SD or number 0). Abbreviations as in Tables I and 3 .
to-treat analysis. Clinical events were defined as death,
myocardial infarction or progressive, medically refractory
ischemia requiring revascularization (bypass surgery or an-
gioplasty) . Intensive therapy resulted in a statistically signif-
icant reduction in clinical events in the subgroup with LDL
cholesterol <90th percentile (p = 0 .01) and a trend toward
fewer events in the subgroup with LDL cholesterol <160
mg/dl (p = 0.05), principally because of a large number of
clinical events in the corresponding conventionally treated,
double-placebo subgroups . There was no such difference for
those with higher LDL cholesterol, perhaps because most or
all of the corresponding conventionally treated patients
received colestipol instead of its placebo .
Discussion
Study data. The FATS patients with lower baseline
levels of LDL cholesterol, using either 90th percentile or
160-mg/di cut points (mean LDL cholesterol 152 and 134
mg/dl, respectively), derived angiographic benefit from in-
tensive lipid-lowering therapy. These treatment subgroups
had a net regression of disease that was particularly striking
for the smaller group with baseline LDL cholesterol <160
mg/dl (Tables 3 and 4) . Their conventionally treated coun-
terparts demonstrated unequivocal net progression of dis-
ease (mean change in severity of proximal stenosis above
+2.096 diameter stenosis), resulting in a highly statistically
significant benefit from intensive therapy in both lower LDL
cholesterol subgroups (p < 0 .005). With treatment, these
patients achieved mean LDL cholesterol levels <100 mg/dl
(Tables 1 and 2), the treatment level currently recommended
for patients with established coronary heart disease (6) .
Patients in the FATS trial with high baseline LDL cho-
lesterol (a%th percentile [mean LDLc 224 mg/dl] or >160
mg/dl [mean LDLc 205 mgldl]) actually tended to obtain less
angiographic benefit than their counterparts with lower LDL
cholesterol (Tables 3 and 4). This apparently diminished
CONV
(n = 15)
INT
(n = 16)
CON ,/*
(n = 31)
INT
h=58)
Mean %a proximal stenosis (±SD)
9 proximal lesions (n = 1,034)
3 .3 ± 3 .3 -4.2±4 .99 1 .6
3,93,9 0.2±4.0
In-treatment LDLc sI00 mg/dl
-5.2±5.4(n=11) -0.1±2.5(n=18)
lit-treatment LDLc/HDLc ratio :52
-5.4±4.5(n=8) -0.1±3.2(n=16)
Proximal lesions with <1013% stenosis (n = 997) 3 .4 ± 3 .9 As= =
1 .6 ± 3 .9 0.5 -4 .0
Proximal lesions with <50% stenosis (n - 847) 3 .1 ± A -2.2±2
.9a 2.1±4 .4 0.9±3.8
Prim:-lion only 7 (47%)
le)2 (I3 e 14 (45%) 15 (26%)
only
1(7%) 11 (69%)l 4(13%) 15 (265- )jj
ii events (total no . of pts at risk)l 6(15)
4(37) 3 (74)
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benefit from intensive therapy in those with higher LDL
cholesterol might be explained in several ways : 1) Those
with higher baseline LDL cholesterol may have had higher
in-treatment levels of LDL cholesterol and apolipoprotein B
and a higher LDL/HDL cholesterol ratio simply because
they started at higher values, and, indeed, this was the case
(Tables I and 2) . However, those intensively treated patients
in the higher LDL cholesterol subgroups for whom in-
treatment LDL cholesterol levels decreased to
25
100 mg/dl
or LDL/HDL cholesterol ratios to 52 .0 did not, on average,
have enhanced regression compared with the remainder of
the subgroup (Tables 3 and 4) . 2) Because the magnitude of
regression has been seen to relate more closely to the
percent change, with treatment, in LDL cholesterol and
1IDI, cholesterol (8), it may be that the patients with higher
ILL cholesterol were less responsive to intensive treatment
in this regard . However, this was not the case (Tables I and
2). The mean percent changes in lipid levels with intensive
therapy in the LDL cholesterol subgroups were remarkably
similar . 3) One could hypothesize that the patients witil
higher baseline LDL cholesterol (and associated lower tri-
glycerides, higher HDL cholesterol and lower frequency of
previous myocardial infarction) have a form of atheroscle-
rotic obstructive disease that is less likely to regress even
with intensive lipid-lowering therapy . Very high levels of
LDL cholesterol over time could result in predominantly
fibrous lesions without a significant lipid component (17) or
lesions in which the lipid is largely cholesterol monohydrate
crystals that persist in experimental regression models
(18,19). This hypothesis is supported by the findings of other
angiographic trials . In the National Heart, Lung, and Blood
Institute (NHLBI) Type 11 Coronary Intervention Study
(20), <7% of a group of patients with severe hypercholes-
terolemia had definite or probable regression despite a mean
LDL cholesterol reduction of 26% and HDL cholesterol
increase of 8% with diet and cholestyramine therapy .
Against this hypothesis, the UC-SCOR trial (21) demon-
strated a mean 1 .5% reduction in percent area stenosis with
very intensive drug therapy in 40 patients with heterozygous
familial hypercholesterolemia . However, these patients
were young (mean age 41 years) and had a low prevalence of
symptomatic coronary heart disease, characteristics com-
patible with less mature and more lipid-rich atherosclerotic
disease (22) that may have more potential for regression .
Finally, the arteriographic treatment benefit relative to con-
ventional therapy may appear blunted in the higher LDL
cholesterol subgroups in part because, by design, most or all
conventionally treated patients in these subgroups were
treated with
diet and colestipol, whereas all conventionally
treated patients in the lower LDL cholesterol subgroups
were treated with diet and a colestipol placebo . However,
in-treatment LDL cholesterol, apolipoprotein B and LDL/
HDL cholesterol ratio were still considerably lower with
intensive therapy, relative to conventional therapy, in the
higher LDL cholesterol subgroups (Tables 1 and 2) . There-
fore the importance of this difference in conventional ther-
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apy as an explanation for the apparently diminished treat-
meat benefit is not obvious .
In addition, the majority of the clinical berivat associated
with intensive therapy in FATS occurred in the lower ILL
cholesterol subgroups, principally because of the large num-
ber of events that occurred with conventional therapy among
these patients (Tables 3 and 4) . This benefit was statistically
significant for the larger subgroup with baseline LDL cho-
lesterol <90th percentile for age (two vs . eight patients with
events, p = 0 .01). These patients had significantly higher
baseline serum triglycerides and lower baseline HDL cho-
lesterol than their high LDL cholesterol counterparts (Ta-
bles I and 2), and indeed this lipid phenotype may have
contributed to a greater risk of coronary heart disease events
without active therapy (16,23), Alternatively, more events
may have occurred in the conventionally treated patients
with lower levels of LDL cholesterol because they did not
receive any active drug therapy . Conventionally treated
patients with pretreatment LDL cholesterol ~90th percen-
tile received colestipol, with a mean 12% reduction in LDL
cholesterol and potentially derived clinical benefit from this
intervention despite net disease progression . Lipid-lowering
therapy, despite the absence of gross lesion regression, may
result in the depletion of foam cells from the fibrous cap and
extracellular lipid from the central core of atherosclerotic
plaques (24,25). These changes may in turn increase plaque
stability (26) and reduce the propensity for plaque rupture,
thrombosis and acute ischemic events (27,28) . In the STARS
trial (29), dietary therapy alone resulted in a significant
reduction in total cardiac events despite a mean reduction in
LDL cholesterol of only 16%, and the POSCH trial (30)
demonstrated a 35% reduction in coronary deaths and non-
fatal myocardial infarction with partial ileal bypass despite,
on average, net progression of disease .
Previous studies . This analysis is limited by its retrospec-
tive design and the small number of patients within the
various LDL cholesterol subgroups . Unfortunately, relevant
data from other trials are limited because most previously
published angiographic trials of lipid-lowering therapy have
not selectively enrolled, or reported findings from, patients
with only borderline or moderate elevations in LDL choles-
terol . Data from the Cholesterol Lowering Atherosclerosis
Study (CLAS) (7) and HARP (31) are most pertinent, but
their results are mixed . In CLAS all patients actively treated
with niacin and colestipol had a mean baseline LDL choles-
terol of 171 mg/dl. A CLAS subgroup with baseline total
cholesterol :5240 mg/dl (and presumably a mean baseline
LDL cholesterol much less than 171 mg/dl) had a benefit
from this drug combination generally comparable to that
achieved among those with cholesterol >240 mgldl . The
recently presented HARP trial (31) did not demonstrate a
statistically significant angiographic or clinical benefit from
intensive
lipid-lowering therapy in a group of patients with
coronary heart disease (mean age 56 years) and "normal"
baseline levels of total cholesterol (180 to 250 mg/dl, mean
total cholesterol 212 mg/dl) despite a mean 42% reduction in
905
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LIM cholesterol and a 1391 increase in HDL cholesterol
relative to control therapy
. Attempts to reconcile these
discrepant data await the full publication of the HARP
results .
. An important principle of clinical
trial analysis is that observations based on subgroups not
defined prospectively should be used only for hypothesis
generation and to provide mechanistic insights . Therefore,
these retrospective subset observations require prospective
caonnhfirnalmatkion .
On the basis of the overall results in FATS, we recom-
mend intensive lipid-lowering therapy for patients with es-
tablished coronaMr heart disease, a family history of premae
ture cardiovascular events and elevated apoli protein B .
Further, on the basis of the subgroup analyses reported here,
and pending their confirmation, physicians should avoid the
temptation to be less committed to intensive therapy in such
high risk patients without very high levels of LDL choles .
terol. Indeed lower levels of LDL cholesterol and, in partic-
ular, levels '9 4q mg/dl, appear to identify patients who will
achieve greabenefit from
intensive therapy. Therapy
should be directed at an LDL cholesterol Uamrgpet s109 mg/dI
in such patients. Similar patients with higher levels of LDL
cholesterol appear to have diminished prospects for disease
regression, even with very effective lipid-lowering therapy .
Nevertheless, intensive therapy tends to retard disease
progression in such patients and appears to confer protection
nst acute ischemic events (29,30) .
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